U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C49H55N9O7
Molecular Weight 882.019
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ELBASVIR

SMILES

CC(C)[C@@]([H])(C(=O)N1CCC[C@@]1([H])c2ncc(-c3ccc4c(c3)cc5-c6ccc(cc6O[C@@]([H])(c7ccccc7)n45)-c8cnc([C@]9([H])CCCN9C(=O)[C@]([H])(C(C)C)N=C(O)OC)[nH]8)[nH]2)N=C(O)OC

InChI

InChIKey=BVAZQCUMNICBAQ-PZHYSIFUSA-N
InChI=1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37-,38-,41-,42-,47-/m0/s1

HIDE SMILES / InChI

Molecular Formula C49H55N9O7
Molecular Weight 882.019
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Targets

Targets

Primary TargetPharmacologyConditionPotency
5 pM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZEPATIER

Approved Use

ZEPATIER® is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adults.

Launch Date

1453939200000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
198 nM
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: GRAZOPREVIR
ELBASVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2710.5 nM × h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: GRAZOPREVIR
ELBASVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
16.5 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: GRAZOPREVIR
ELBASVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
24 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: GRAZOPREVIR
ELBASVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.1%
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: GRAZOPREVIR
ELBASVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 1 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 34.6 years
Health Status: unhealthy
Age Group: 34.6 years
Sex: M
Sources:
PubMed

PubMed

TitleDatePubMed
Grazoprevir + elbasvir for the treatment of hepatitis C virus infection.
2016
The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
2016 May
Patents

Sample Use Guides

ZEPATIER is a two-drug, fixed-dose combination product containing 50 mg of elbasvir and 100 mg
Route of Administration: Oral
Elbasvir was highly potent in GT1a wild-type replicon cells, with 90% effective concentration (EC90) value of 0.006 nM.
Substance Class Chemical
Created
by admin
on Sat Jun 26 15:20:59 UTC 2021
Edited
by admin
on Sat Jun 26 15:20:59 UTC 2021
Record UNII
632L571YDK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ELBASVIR
DASH   INN   USAN   WHO-DD  
INN   USAN  
Official Name English
ELBASVIR COMPONENT OF ZEPATIER
Common Name English
ZEPATIER COMPONENT OF ELBASVIR
Common Name English
ELBASVIR [JAN]
Common Name English
ELBASVIR [MI]
Common Name English
ELBASVIR [ORANGE BOOK]
Common Name English
ELBASVIR [WHO-DD]
Common Name English
CARBAMIC ACID, N,N'-(((6S)-6-PHENYL-6H-INDOLO(1,2-C)(1,3)BENZOXAZINE-3,10-DIYL)BIS(1H-IMIDAZOLE-5,2-DIYL-(2S)-2,1-PYRROLIDINEDIYL((1S)-1-(1-METHYLETHYL)-2-OXO-2,1-ETHANEDIYL)))BIS-, C,C'-DIMETHYL ESTER
Common Name English
MK-8742
Code English
ELBASVIR [INN]
Common Name English
ELBASVIR [USAN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000191256
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
WHO-ATC J05AP54
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C166892
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
PRIMARY
WIKIPEDIA
ELBASVIR
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
PRIMARY
RXCUI
1734628
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
PRIMARY
EPA CompTox
1370468-36-2
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
PRIMARY
LACTMED
Elbasvir
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
PRIMARY
CAS
1370468-36-2
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
PRIMARY
DRUG CENTRAL
5080
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
PRIMARY
INN
9851
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
PRIMARY
EVMPD
SUB174125
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
PRIMARY
MERCK INDEX
M11946
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
PRIMARY
ChEMBL
CHEMBL3039514
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
PRIMARY
FDA UNII
632L571YDK
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
PRIMARY
NDF-RT
N0000190113
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
PRIMARY Breast Cancer Resistance Protein Inhibitors [MoA]
DRUG BANK
DB11574
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
PRIMARY
PUBCHEM
71661251
Created by admin on Sat Jun 26 15:20:59 UTC 2021 , Edited by admin on Sat Jun 26 15:20:59 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
IC50
TRANSPORTER -> SUBSTRATE
BINDER->LIGAND
BINDING
BINDER->LIGAND
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> INHIBITOR
IC50
TRANSPORTER -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC